All patients receive individualized investigational TIL therapy

Every patient who meets eligibility criteria and enrolls in an Iovance clinical trial will receive individualized investigational TIL therapy made from their own immune cells. There are no placebo arms. In trials where we are exploring combination treatments, every patient will receive their individualized cell therapy as part of the combination. Trial medication and trial-related care are provided at no cost.

To learn more, please call 1-866-565-4410 or email clinical.inquiries@iovance.com.

About investigational TIL therapy

TIL are naturally occurring white blood cells that fight cancer and are usually found in tumors or lymph nodes. When healthy and plentiful, TIL recognize, attack and kill cancer cells. TIL therapy is being investigated in solid tumors. In investigational TIL therapy, a patient’s naturally occurring TIL are harvested, multiplied into the billions and administered back to the patient as a one-time treatment.

Learn more about TIL therapy

Clinical trials in solid tumors

Metastatic Melanoma

The most dangerous aspect of melanoma is its ability to spread. Stage 4 melanoma has typically spread through the lymph nodes to distant sites in the body and/or to the body’s organs. The liver, lungs, bones and brain are most often affected by these metastases. Over 300,000 cases of malignant skin melanoma are diagnosed worldwide each year.1 They cause approximately 62,000 deaths, including approximately 12,000 deaths in the US alone.1

IOV-COM-202 trial overview

Iovance is conducting a Phase 2, multicenter trial in patients with unresectable or metastatic melanoma as part of a broader trial in multiple types of solid tumors.

View trial information

Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is responsible for approximately two million deaths worldwide each year,1 including nearly 132,000 deaths in the US alone.2 The disease can affect anyone, and many people diagnosed today have either stopped smoking years earlier or never smoked. The main types of lung cancer are small cell lung cancer (SCLC) and NSCLC, and they are treated differently. NSCLC begins in the epithelial cells of the lungs. SCLC begins in the nerve cells or hormone-producing cells of the lung.

IOV-LUN-202 trial overview

Iovance is conducting a Phase 2, multicenter trial in patients with recurrent or metastatic NSCLC.

View trial information

 

IOV-COM-202 trial overview

Iovance is conducting a Phase 2, multicenter trial in patients with recurrent or metastatic NSCLC as part of a broader trial in multiple types of solid tumors.

View trial information

Cervical Cancer

The main types of cervical cancer are squamous cell carcinoma and adenocarcinoma. Squamous cell carcinoma begins in the thin, flat cells that line the cervix. Adenocarcinoma begins in cervical cells that make mucus and other fluids. Despite the availability of the human papilloma virus (HPV) vaccine, nearly 19,000 new cases of cervical cancer are diagnosed in the US each year and are responsible for approximately 8,000 deaths.1

C-145-04 trial overview

Iovance is conducting a Phase 2, multicenter trial to evaluate efficacy and safety using autologous TIL in patients with recurrent, metastatic or persistent cervical carcinoma.

View trial information

Head and Neck Squamous Cell Carcinoma (HNSCC)

Cancers of the oropharynx and hypopharynx are, like oral cancer and cancer of the larynx, usually squamous cell carcinomas which originate in the epithelial cells that line the throat. Despite the availability of the HPV vaccine, cancers of the oropharynx and hypopharynx are responsible for approximately 265,000 deaths worldwide each year.3

IOV-COM-202 trial overview

Iovance is conducting a Phase 2, multicenter trial in patients with recurrent and/or metastatic HNSCC as part of a broader trial in multiple types of solid tumors.

View trial information

Clinical trials in blood cancers

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

CLL and SLL are two types of blood cancer that primarily impact older adults. While both CLL and SLL affect lymphocytes, the cancers for each type are found in different sites: in CLL, the blood and bone marrow; in SLL, the lymph nodes. More than 20,000 people in the US are diagnosed with CLL or SLL each year.2 The disease is considered relapsed when it returns after a period of remission and refractory when it does not respond to treatment.

IOV-CLL-01 trial overview

Iovance is conducting a Phase 1/2 trial to evaluate the safety and efficacy of autologous PBL therapy in patients with relapsed or refractory CLL or SLL.

View trial information

References: 1. IHME: Global Health Data Exchange. Seattle, WA: Institute. For Health Metrics and Evaluation; 2022. https://ghdx.healthdata.org/gbd-results-tool. Accessed April 11, 2022. 2. NCI: Surveillance, Epidemiology, and End Results Program. Bethesda, MD: National Cancer Institute; Updated February 2022. https://seer.cancer.gov/statfacts. Accessed April 11, 2022. 3. ASCO: Cancer.Net. Alexandria, VA: American Society of Clinical Oncology; 2022. https://www.cancer.net. Accessed May 31, 2022.

View Our Expanded Access Policy

TIL and PBL therapies are investigational therapies and have not been approved for any indication by the Food and Drug Administration (FDA) or any other regulatory agency. The safety and efficacy of these therapies have not been determined.